Home Cart Sign in  
Chemical Structure| 477575-56-7 Chemical Structure| 477575-56-7

Structure of PHA-665752
CAS No.: 477575-56-7

Chemical Structure| 477575-56-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PHA-665752 is a selective, ATP-competitive inhibitor of c-Met kinase catalytic activity (Ki = 4 nM; IC50 = 9 nM), demonstrating over 50-fold selectivity for c-Met compared to various other tyrosine and serine-threonine kinases. PHA-665752 induces apoptosis, cell cycle arrest, and exhibits cytoreductive antitumor activity.

Synonyms: PHA-665752

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PHA-665752

CAS No. :477575-56-7
Formula : C32H34Cl2N4O4S
M.W : 641.61
SMILES Code : O=C(C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)S(=O)(CC4=C(C=CC=C4Cl)Cl)=O)=O)=C1C)C)N5[C@H](CCC5)CN6CCCC6
Synonyms :
PHA-665752
MDL No. :MFCD07772270
InChI Key :OYONTEXKYJZFHA-SSHUPFPWSA-N
Pubchem ID :10461815

Safety of PHA-665752

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PHA-665752

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SNU1076 1 μM 24 h To study the effect of MET activation on cetuximab efficacy, results showed that PHA-665752 reversed MAPK pathway inhibition PMC6554031
HSC4 1 μM 24 h To study the effect of MET activation on cetuximab efficacy, results showed that PHA-665752 reversed MAPK pathway inhibition PMC6554031
44As3 cells 100 nM or 300 nM 2 h To evaluate the inhibitory effect of PHA-665752 on Met phosphorylation in 44As3 cells PMC4317844
58As9 cells 100 nM or 300 nM 2 h To evaluate the inhibitory effect of PHA-665752 on Met phosphorylation in 58As9 cells PMC4317844
FG cells 0.1 μM 48 h To investigate the effect of PHA-665752 on FOXM1 expression in FG cells, results showed that PHA-665752 inhibited the HGF/Met signaling pathway, thereby reducing FOXM1 expression. PMC4985506
PANC-1 cells 0.1 μM 48 h To investigate the effect of PHA-665752 on the expression of FOXM1 downstream target genes in PANC-1 cells, results showed that PHA-665752 inhibited the HGF/Met signaling pathway, thereby reducing the expression of FOXM1 downstream target genes. PMC4985506
GTL-16 100 nM 4 h To evaluate the inhibitory effect of PHA-665752 on MET phosphorylation PMC7802886
HT29 100 nM 4 h To evaluate the inhibitory effect of PHA-665752 on MET phosphorylation PMC7802886
A549 100 nM 4 h To evaluate the inhibitory effect of PHA-665752 on MET phosphorylation PMC7802886
GTL16 cells 250 nM PHA-665752 significantly impaired the viability and growth ability of GTL16 cells, but upon stimulation with EGF or HRG1-β1, cells were able to partially overcome the inhibitory effect of PHA-665752. PMC2892452
SNU5 50 nM PHA-665752 significantly impaired the viability and growth ability of these cells, but upon stimulation with EGF or HRG1-β1, cells were able to partially overcome the inhibitory effect of PHA-665752. PMC2892452
MRC-5 cells 1 µM 24 h Inhibition of HGF signaling to study the effect of PHA-665752 on fibronectin expression in MRC-5 cells. Results showed that PHA-665752 significantly inhibited the suppressive effects of OSM-MSC conditioned medium on fibronectin expression. PMC5442768
MESO924 1 µM 72 h PHA-665752 exhibited antiproliferative effects in MESO924 cells by inhibiting MET-dependent PI3K/AKT and RAF/MAPK signaling pathways PMC4021537
MESO257 1 µM 72 h PHA-665752 exhibited antiproliferative effects in MESO257 cells by inhibiting MET-dependent PI3K/AKT and RAF/MAPK signaling pathways PMC4021537
MESO296 1 µM 72 h PHA-665752 exhibited antiproliferative effects in MESO296 cells by inhibiting MET-dependent PI3K/AKT and RAF/MAPK signaling pathways PMC4021537
MESO428 1 µM 72 h PHA-665752 exhibited antiproliferative effects in MESO428 cells by inhibiting MET-dependent PI3K/AKT and RAF/MAPK signaling pathways PMC4021537

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice CAL33 cell line-derived xenograft model Oral 30 mg/kg Once daily for 30 days To study the effect of PHA-665752 on cetuximab efficacy, results showed that PHA-665752 restored sensitivity to cetuximab PMC6554031
BALB/c nude mice Peritoneal dissemination model Intraperitoneal injection 10 mg/kg Three times per week for 9-11 days or 16-18 days To evaluate the inhibitory effect of PHA-665752 on peritoneal dissemination of 44As3 and 58As9 cells PMC4317844
Nude mice Pancreatic cancer xenograft model Intravenous injection 15 mg/kg Once daily for 21 days To investigate the effect of PHA-665752 on tumor growth in a pancreatic cancer xenograft model, results showed that the combination of PHA-665752 and TST significantly inhibited tumor growth. PMC4985506
Nude mice GTL-16 tumor xenograft model Intraperitoneal injection 25 mg/kg or 50 mg/kg Once daily for 8-10 days To evaluate the inhibitory effect of PHA-665752 on GTL-16 tumor growth and MET phosphorylation PMC7802886

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02002416 - Unknown December 2014 China, Guangdong ... More >> Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510060 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.56mL

0.31mL

0.16mL

7.79mL

1.56mL

0.78mL

15.59mL

3.12mL

1.56mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories